<unk>  <unk>  is an experimental form of radiotherapy that utilizes a<unk>  beam that interacts with<unk>  injected to a patient.<unk>  depends on the interaction of slow<unk> s with<unk> -10 to produce alpha particles and lithium nuclei, without producing other types of ionizing radiation. Patients are first given an intravenous injection of a<unk> -10 tagged chemical that preferentially binds to tumor cells. In clinical trials performed so far the<unk> s are created in a nuclear reactor, but particle accelerators may also be used to collide protons into targets made of lithium or beryllium. The<unk> s pass through a moderator, which shapes the<unk>  energy spectrum suitable for<unk>  treatment. Before entering the patient the<unk>  beam is shaped by a beam collimator. While passing through the tissue of the patient, the<unk> s are slowed by collisions and become low energy thermal<unk> s. The thermal<unk> s undergo reaction with the<unk> -10 nuclei, forming a compound nucleus (excited<unk> -11) which then promptly disintegrates to lithium-7 and an alpha particle. Both the alpha particle and the lithium ion produce closely spaced ionizations in the immediate vicinity of the reaction, with a range of approximately 10 micrometres, or one cell diameter. This technique is advantageous since the radiation damage occurs over a short range and thus normal tissues can be spared.<unk>  has been experimentaly tested primarily as an alternative treatment for malignant brain tumors called glioblastomas. Although there are reports of some successful outcomes, this approach has not yet been shown to be superior to other current therapies. Hence,<unk>  has not entered routine clinical use.
Boron Neutron Capture Therapy
Photothermal Therapy
Targeted therapy
Low-dose chemotherapy
Antibody-Directed Enzyme Prodrug Therapy
Chemotherapy
Hamman-Rich syndrome surgery
Oligoastrocytoma surgery